Academia.eduAcademia.edu

Selective inhibitors of the osteoblast proteasome stimulate

AI-generated Abstract

Selective inhibitors of the osteoblast proteasome have been demonstrated to significantly enhance bone formation in vitro and in vivo. Specific proteasome inhibitors, such as epoxomicin and proteasome inhibitor-1, have been shown to increase bone volume and formation rates by over 70% in mice, correlating with elevated mRNA expression of BMP-2. Mechanistic studies indicate that these inhibitors regulate BMP-2 gene expression through the inhibition of Gli3 proteolytic processing, suggesting potential therapeutic applications in managing bone loss diseases.